Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance

Xue WEN; Yujing HE; Qianqian YUAN; Chuyi LI; Lixia LU; Xiaohui YU; Jiucong ZHANG

doi:10.3969/j.issn.1001-5256.2023.04.011

Volume 39 Issue 4

Apr. 2023

Turn off MathJax

Article Contents

Article Navigation > Journal of Clinical Hepatology > 2023 > 39(4): 810-817

PDF( 1814 KB)

Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2023.04.011

Xue WEN^{1, 2},
Yujing HE¹,
Qianqian YUAN¹,
Chuyi LI¹,
Lixia LU¹,
Xiaohui YU^{1
,
,
,},
Jiucong ZHANG^{1
,
,
,}

1.
Department of Gastroenterology, The 940^th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army, Lanzhou 730050, China
2.
School of Clinical Medicine, Ningxia Medical University, Yinchuan 750000, China

Research funding:

National Natural Science Foundation of China (Youth Foundation) (81500454);

Science and Technology Program of Gansu Province (21JR7RA017);

Gansu Provincial Clinical Research Center for Severe Disease of Digestive System (20JR10RA107)

More Information

Corresponding author: YU Xiaohui, yuxiaohui528@126.com (ORCID: 0000-0002-8633-3281); ZHANG Jiucong, zhangjiucong@163.com (ORCID: 0000-0003-4006-3033)
Received Date: 2022-09-07
Accepted Date: 2022-10-09
Published Date: 2023-04-20

Abstract

Abstract

Objective To investigate the expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its correlation with clinical indicators. Methods A total of 20 patients with chronic hepatitis B (CHB), 68 patients with hepatitis B cirrhosis, and 20 healthy controls who attended The 940^th Hospital of Joint Logistics Support Force of Chinese People's Liberation Army from October 2020 to November 2021 were enrolled. According to Child-Pugh class, the patients with hepatitis B cirrhosis were divided into Child-Pugh class A group with 24 patients, Child-Pugh class B group with 24 patients, and Child-Pugh class C group with 20 patients. After peripheral blood samples were collected to isolate serum and peripheral blood mononuclear cells (PBMCs), flow cytometry was used to measure the expression of membrane-bound Sema4D (mSema4D)⁺CD4⁺ T cells and mSema4D⁺CD8⁺ T cells in PBMCs, and ELISA was used to measure the expression of soluble Sema4D (sSema4D) in serum; their correlation with viral replication and liver inflammation markers was analyzed. A one-way analysis of variance was used for comparison of normally distributed continuous data between multiple groups, and the least significant difference t-test was used for further comparison between two groups; the Kruskal-Wallis H test was used for comparison of non-normally distributed continuous data between multiple groups, and the Mann-Whitney U test was used for further comparison between two groups; a Spearman correlation analysis was also performed. Results There were significant differences in the expression of mSema4D⁺CD4⁺ T cells and mSema4D⁺CD8⁺ T cells between the CHB group, the hepatitis B cirrhosis group, and the control group (F=43.092 and 13.344, both P < 0.001), while there were significant differences between any two groups (P < 0.05). The expression levels of mSema4D⁺CD4⁺ T cells and mSema4D⁺CD8⁺ T cells gradually decreased with increasing Child-Pugh class (F=14.093 and 17.154, both P < 0.05), and there were significant differences between any two groups (P < 0.05). The content of sSema4D was 1.54(1.42-1.71) ng/mL in the control group, 1.08(1.07-1.38) ng/mL in the CHB group, and 4.87(2.13-14.97) ng/mL in the hepatitis B cirrhosis group, with a significant difference between the three groups (H=32.366, P < 0.001) and between any two groups (P < 0.05). The content of sSema4D was 2.42(0.59-5.65) ng/mL in the Child-Pugh class A group, 4.92(2.75-12.73) ng/mL in the Child-Pugh class B group, and 14.18(4.59-18.43) ng/mL in the Child-Pugh class C group, with a significant difference between the three groups (H=11.889, P=0.003) and between any two groups (P < 0.05). In patients with hepatitis B cirrhosis, the level of sSema4D was positively correlated with the levels of alanine aminotransferase (ALT) and HBV DNA quantification (r=0.294 and 0.430, both P < 0.05). Conclusion Sema4D is lowly expressed on T cell membrane and highly expressed in serum of patients with hepatitis B cirrhosis, and sSema4D may be involved in the development and progression of hepatitis B cirrhosis by affecting the levels of ALT and HBV DNA.
- Liver Cirrhosis,
- Hepatitis B,
- Sema4D,
- T-Lymphocytes

FullText(HTML)

References(34)

References

[1]	SCHWEITZER A, HORN J, MIKOLAJCZYK RT, et al. Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013[J]. Lancet, 2015, 386(10003): 1546-1555. DOI: 10.1016/S0140-6736(15)61412-X.
[2]	SHI W, KUMANOGOH A, WATANABE C, et al. The class Ⅳ semaphorin CD100 plays nonredundant roles in the immune system: defective B and T cell activation in CD100-deficient mice[J]. Immunity, 2000, 13(5): 633-642. DOI: 10.1016/s1074-7613(00)00063-7.
[3]	DELAIRE S, BILLARD C, TORDJMAN R, et al. Biological activity of soluble CD100. Ⅱ. Soluble CD100, similarly to H-SemaIII, inhibits immune cell migration[J]. J Immunol, 2001, 166(7): 4348-4354. DOI: 10.4049/jimmunol.166.7.4348.
[4]	ELHABAZI A, DELAIRE S, BENSUSSAN A, et al. Biological activity of soluble CD100. I. The extracellular region of CD100 is released from the surface of T lymphocytes by regulated proteolysis[J]. J Immunol, 2001, 166(7): 4341-4347. DOI: 10.4049/jimmunol.166.7.4341.
[5]	LIU B, MA Y, ZHANG Y, et al. CD8^low CD100^- T cells identify a novel CD8 T cell subset associated with viral control during human hantaan virus infection[J]. J Virol, 2015, 89(23): 11834-11844. DOI: 10.1128/JVI.01610-15.
[6]	YOSHIDA Y, OGATA A, KANG S, et al. Semaphorin 4D contributes to rheumatoid arthritis by inducing inflammatory cytokine production: pathogenic and therapeutic implications[J]. Arthritis Rheumatol, 2015, 67(6): 1481-1490. DOI: 10.1002/art.39086.
[7]	ZHANG C, QIAO H, GUO W, et al. CD100-plexin-B1 induces epithelial-mesenchymal transition of head and neck squamous cell carcinoma and promotes metastasis[J]. Cancer Lett, 2019, 455: 1-13. DOI: 10.1016/j.canlet.2019.04.013.
[8]	Chinese Society of Infectious Diseases, Chinese Medical Association; Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[9]	BASILE JR, HOLMBECK K, BUGGE TH, et al. MT1-MMP controls tumor-induced angiogenesis through the release of semaphorin 4D[J]. J Biol Chem, 2007, 282(9): 6899-6905. DOI: 10.1074/jbc.M609570200.
[10]	KUMANOGOH A, WATANABE C, LEE I, et al. Identification of CD72 as a lymphocyte receptor for the class Ⅳ semaphorin CD100: a novel mechanism for regulating B cell signaling[J]. Immunity, 2000, 13(5): 621-631. DOI: 10.1016/s1074-7613(00)00062-5.
[11]	KUKLINA EM, NEKRASOVA IV. New aspects of the Seam4D-dependent control of lymphocyte activation[J]. Dokl Biol Sci, 2017, 473(1): 84-88. DOI: 10.1134/S0012496617020028.
[12]	MALEKI KT, CORNILLET M, BJÖRKSTRÖM NK. Soluble SEMA4D/CD100: A novel immunoregulator in infectious and inflammatory diseases[J]. Clin Immunol, 2016, 163: 52-59. DOI: 10.1016/j.clim.2015.12.012.
[13]	HE Y, GUO Y, FAN C, et al. Interferon-α-Enhanced CD100/Plexin-B1/B2 interactions promote natural killer cell functions in patients with chronic hepatitis C virus infection[J]. Front Immunol, 2017, 8: 1435. DOI: 10.3389/fimmu.2017.01435.
[14]	CH'NG ES, KUMANOGOH A. Roles of Sema4D and Plexin-B1 in tumor progression[J]. Mol Cancer, 2010, 9: 251. DOI: 10.1186/1476-4598-9-251.
[15]	TANG GJ, YOU J, LIU HE, et al. Role of T helper 17 cell/regulatory T cell imbalance in the progression of HBV-related liver diseases[J]. J Clin Hepatol, 2021, 37(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2021.02.035. 唐光俊, 游晶, 刘怀鄂, 等. 辅助性T淋巴细胞17/调节性T淋巴细胞比值失衡在HBV相关肝脏疾病进展中的作用[J]. 临床肝胆病杂志, 2021, 37(2): 414-418. DOI: 10.3969/j.issn.1001-5256.2021.02.035.
[16]	ASABE S, WIELAND SF, CHATTOPADHYAY PK, et al. The size of the viral inoculum contributes to the outcome of hepatitis B virus infection[J]. J Virol, 2009, 83(19): 9652-9662. DOI: 10.1128/JVI.00867-09.
[17]	YANG PL, ALTHAGE A, CHUNG J, et al. Immune effectors required for hepatitis B virus clearance[J]. Proc Natl Acad Sci U S A, 2010, 107(2): 798-802. DOI: 10.1073/pnas.0913498107.
[18]	WANG Y, XU N, LI XX. An analysis of T lymphocyte level inhepatitis B virus infected patients with different degree of inflammatory gastric mucosal lessons[J]. Chin Hepatol, 2021, 26(11): 1236-1239. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.014. 王炎, 许娜, 李小心. 乙型肝炎患者的T淋巴细胞水平与胃黏膜炎性病变程度[J]. 肝脏, 2021, 26(11): 1236-1239. DOI: 10.14000/j.cnki.issn.1008-1704.2021.11.014.
[19]	LIU X, HE L, HAN J, et al. Association of neutrophil-lymphocyte ratio and T lymphocytes with the pathogenesis and progression of HBV-associated primary liver cancer[J]. PLoS One, 2017, 12(2): e0170605. DOI: 10.1371/journal.pone.0170605.
[20]	CHU YL, GU HL, LAN J, et al. Biomarkers in peripheral blood T-lymphocyte subsets of patients with chronic hepatitis B and its advanced liver diseases[J]. Pract Prey Med, 2016, 23(7): 873-876. DOI: 10.3969/j.issn.1006-3110.2016.07.034. 楚玉兰, 顾洪立, 兰继, 等. 慢性乙型肝炎及后期肝病患者外周血T淋巴细胞亚群标志的研究[J]. 实用预防医学, 2016, 23(7): 873-876. DOI: 10.3969/j.issn.1006-3110.2016.07.034.
[21]	YANG S, WANG L, PAN W, et al. MMP2/MMP9-mediated CD100 shedding is crucial for inducing intrahepatic anti-HBV CD8 T cell responses and HBV clearance[J]. J Hepatol, 2019, 71(4): 685-698. DOI: 10.1016/j.jhep.2019.05.013.
[22]	LIU HJ. The expression of soluble Sema4D in the serum of patients with chronic hepatitis B and its clinical significance[D]. Lanzhou: Gansu University of Traditional Chinese Medicine, 2021. DOI: 10.27026/d.cnki.ggszc.2021.000017. 刘亨晶. 可溶性Sema4D在慢性乙型肝炎患者血清中的表达及其临床意义[D]. 兰州: 甘肃中医药大学, 2021. DOI: 10.27026/d.cnki.ggszc.2021.000017.
[23]	WANG GL, WANG ZH, ZHANG XL, et al. The relationship between serum Sema4D, BMP-4, AFU and clinicopathological characteristics and prognostic survival of patients with hepatitis B related liver cancer[J]. Chin J Surg Oncol, 2021, 13(2): 185-190. DOI: 10.3969/j.issn.1674-4136.2021.02.017. 王桂玲, 王治海, 张香玲, 等. 血清Sema4D、BMP-4、AFU与乙肝相关肝癌患者临床病理特征及预后的关系[J]. 中国肿瘤外科杂志, 2021, 13(2): 185-190. DOI: 10.3969/j.issn.1674-4136.2021.02.017.
[24]	ZHAO HY, YANG D, HONG W, et al. Analysis of HBV-DNA level, HBV-M and lymphocyte subtype characteristics in patients with chronic hepatitis B and hepatitis B cirrhosis[J]. Guangdong Med J, 2019, 40(3): 432-435. DOI: 10.13820/j.cnki.gdyx.20183783. 赵海燕, 杨东, 洪伟, 等. 慢性乙型肝炎、乙肝肝硬化患者中HBV-DNA水平、HBV-M、淋巴细胞亚型特点分析[J]. 广东医学, 2019, 40(3): 432-435. DOI: 10.13820/j.cnki.gdyx.20183783.
[25]	ERIKSSON EM, MILUSH JM, HO EL, et al. Expansion of CD8⁺ T cells lacking Sema4D/CD100 during HIV-1 infection identifies a subset of T cells with decreased functional capacity[J]. Blood, 2012, 119(3): 745-755. DOI: 10.1182/blood-2010-12-324848.
[26]	LIU ZM, ZOU C. The correlation of FibroScan parameter with serum inflammationindexes, collagen metabolism indexes and fibrosis indexes inpatients with hepatitis B cirrhosis[J]. J Hanan Med Coll, 2018, 24(5): 597-600. DOI: 10.13210/j.cnki.jhmu.20180227.006. 刘祖明, 邹灿. 乙肝肝硬化患者FibroScan参数与血清炎症指标、胶原代谢指标及纤维化指标的相关性[J]. 海南医学院学报, 2018, 24(5): 597-600. DOI: 10.13210/j.cnki.jhmu.20180227.006.
[27]	WANG L, LIAO Y, YANG R, et al. Sja-miR-71a in Schistosome egg-derived extracellular vesicles suppresses liver fibrosis caused by schistosomiasis via targeting semaphorin 4D[J]. J Extracell Vesicles, 2020, 9(1): 1785738. DOI: 10.1080/20013078.2020.1785738.
[28]	LE HW, WANG YY. Change of blood coagulation, fibrinolysis and danti-coagulation indexes during the progress of chronic hepatitis B[J]. Lab Med Clin, 2020, 17(6): 755-757. DOI: 10.3969/j.issn.1672-9455.2020.06.010. 乐华文, 王依屹. 凝血、纤溶和抗凝指标在慢性乙型肝炎病情进展中的变化规律[J]. 检验医学与临床, 2020, 17(6): 755-757. DOI: 10.3969/j.issn.1672-9455.2020.06.010.
[29]	LUO ZF, HE YM, XU Y. The role and mechanism of CD100 in the secretion of IgA by B lymphocytes in the pathogenesis of henoch-schönlein purpura[J]. Sichuan Med J, 2020, 41(7): 701-706. DOI: 10.16252/j.cnki.issn1004-0501-2020.07.008. 罗卓夫, 何渊民, 许飏. CD100在参与过敏性紫癜发病中B淋巴细胞分泌IgA的作用及机制初探[J]. 四川医学, 2020, 41(7): 701-706. DOI: 10.16252/j.cnki.issn1004-0501-2020.07.008.
[30]	MOVILA A, MAWARDI H, NISHIMURA K, et al. Possible pathogenic engagement of soluble Semaphorin 4D produced by γδT cells in medication-related osteonecrosis of the jaw (MRONJ)[J]. Biochem Biophys Res Commun, 2016, 480(1): 42-47. DOI: 10.1016/j.bbrc.2016.10.012.
[31]	WANG Y, ZHU YZ, CHONG Y, et al. Research of the relationship between serum HBV-DNA content and ALT level in hepatitis B patients[J]. Prog Mod Biomed, 2014, 14(29): 5735-5737, 5746. DOI: 10.13241/j.cnki.pmb.2014.29.035. 王元, 朱亚洲, 种莹, 等. 乙肝患者血清的HBV-DNA含量与ALT水平的关系研究[J]. 现代生物医学进展, 2014, 14(29): 5735-5737, 5746. DOI: 10.13241/j.cnki.pmb.2014.29.035.
[32]	HE XQ, SONG XM, GUO JJ. A review of hepatitis B virus infection and hepatitis B-related hepatitis cancer disease development[J]. Science Consultation (Science and Technology Management), 2018(14): 53-55. DOI: 10.3969/j.issn.1671-4822.2018.14.037. 贺小琴, 宋孝美, 郭进军. 乙肝病毒感染与乙肝相关肝癌疾病发展的综述[J]. 科学咨询(科技·管理), 2018(14): 53-55. DOI: 10.3969/j.issn.1671-4822.2018.14.037.
[33]	CHEN JD, ZHAI RR, LIU C, et al. Study on the correlation between serum hepatitis B B virus core antibody and alanine aminotransferase, hepatitis B virus nucleic acid copy number in patients with chronic hepatitis B cirrhosis[J]. Clin J Med Offic, 2021, 49(8): 906-907. DOI: 10.16680/j.1671-3826.2021.08.18. 陈家东, 翟荣荣, 刘灿, 等. 慢性乙肝肝硬化患者血清乙肝病毒核心抗体定量与谷丙转氨酶、乙肝病毒核酸拷贝数相关性研究[J]. 临床军医杂志, 2021, 49(8): 906-907. DOI: 10.16680/j.1671-3826.2021.08.18.
[34]	HE Y, LI BJ, ZHOU Y, et al. Alteration of CD100 expression on natural killer cells in chronic patients with hepatitis C virus before and after initiation of antiviral treatment[J]. Chin J Cell Mol Immunol, 2014, 30(8): 856-860. DOI: 10.13423/j.cnki.cjcmi.006983. 何瑜, 李冰洁, 周云, 等. 慢性丙型病毒性肝炎患者抗病毒治疗前后自然杀伤细胞CD100表达水平变化[J]. 细胞与分子免疫学杂志, 2014, 30(8): 856-860. DOI: 10.13423/j.cnki.cjcmi.006983.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(3)

Get Citation

PDF

XML

Article Metrics

Article views (411) PDF downloads(41)

Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2023.04.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Expression of Sema4D in peripheral blood T cells and serum of patients with hepatitis B cirrhosis and its clinical significance

DOI: 10.3969/j.issn.1001-5256.2023.04.011

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content